Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder
Lithium (Li), the first-line treatment of bipolar disorder, was first developed as an immediate-release form with a routine therapeutic drug monitoring 12 h after the last dose. In Europe, the most commonly prescribed form is a sustained release (srLi). Yet no pharmacokinetics (PK) study has been published of srLi, administered once a day, in adults. The present study describes srLi PK in the serum and erythrocytes of bipolar patients.
To assess srLi PK, we studied prospectively 17 French bipolar patients on a median dose of 1000 mg (600–1600) for at least 2 years. Serum (S), erythrocyte (E) concentrations, and urinary (U) amount were collected over 8 h after 15 days of morning intake using monitoring electronic medical system (MEMs). Population PK parameters were estimated using the SAEM algorithm (MONOLIX 4.3.3 software).
Using a population approach, we built a PK population model of srLi including one S compartment (VS = 23.0 L, ClS = 1.21 L h−1), one E compartment (VE = 64.7 L, ClSE = 3.63 L h−1, ClES = 9.46 L h−1), and one U compartment (F = 0.62) and estimate the ratio of concentrations to Li in E over S at 0.38 with 27% between-subject variability.
This is a PK model of srLi once a day in bipolar patients using a population approach simultaneously describing Li concentrations in serum, erythrocytes, and urine which provide an estimate of the ratio of concentration in erythrocyte over serum and its between-subject variability (BSV).
KeywordsLithium Pharmacokinetics Bipolar disorder Sustained release
Part of the content of this work was presented at Population Approach Group of Europe Meeting, held in Budapest 2017.
Wrote manuscript: CC, JB, XD, FM, FB.
Designed research: FM, FB, SS, XD, CC.
Performed research: FB, SS, MJ.
Analyzed data: CC, FM, JB.
Contributed analytical tools: SE, JP, NDO.
This study was supported by a grant from Ministry of research of France (PRES 2013).
Compliance with ethical standards
The study was conducted in accordance with good clinical practice and was approved by the ethics committee (IRB CPP IDF VI 2008-A01465-50). All patients or their legal representative signed an informed consent form for GAN and the ancillary pharmacokinetic study. Clinical Trial Registration of GAN study: http://www.clinicaltrials.gov; unique identifier: NCT02627404.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ (2011) Grand challenges in global mental health. Nature 475(7354):27–30CrossRefGoogle Scholar
- 7.Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre R, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15(1):1–44CrossRefGoogle Scholar
- 12.Résumé des Caractéristiques du Produit [Internet]. [cited 2017 Jun 29]. Available from: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0121511.htm
- 15.Couffignal C, Chevillard L, Balkhi SE, Cisternino S, Declèves X (2017) The pharmacokinetics of lithium. In: Malhi GS, Masson M, Bellivier F, editors. The science and practice of lithium therapy [Internet]. Springer International Publishing [cited 2017 Apr 28]. p. 25–53. Available from: http://link.springer.com/chapter/10.1007/978-3-319-45923-3_2
- 26.Hoegberg LCG, Jürgens G, Zederkof VW, Holgersson B, Andersson JE, Dalhoff KP, Larsen EB, Angelo HR (2012) A computerised sampling strategy for therapeutic drug monitoring of lithium provides precise estimates and significantly reduces dose-finding time. Basic Clin Pharmacol Toxicol 110(3):259–263CrossRefGoogle Scholar
- 38.Nguyen T, Mouksassi M-S, Holford N, Al-Huniti N, Freedman I, Hooker AC et al (2016) Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst PharmacolGoogle Scholar
- 47.Murphy JE (2011) Clinical pharmacokinetics. ASHP, 433 pGoogle Scholar
- 50.Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P (2017) Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother 72(1):190–199CrossRefGoogle Scholar